MDM2, MDMX and p53 in oncogenesis and cancer therapy

Cited by (998)

Items 201–300 of 998

1. CircKDM4C upregulates P53 by sponging hsa‐let‐7b‐5p to induce ferroptosis in acute myeloid leukemia
   Lihua Dong, Jingjing Huang, Peng Zu, Jing Liu, Xue Jun Gao, Jian‐wei Du, Yufu Li · 2021 · Environmental Toxicology
2. Wild type p53 reactivation: From lab bench to clinic
   Galina Selivanova · 2014 · FEBS Letters
3. Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library
   Can Huang, Shourong Wu, Hong Ji, Xuesong Yan, Yudan Xie, Saomi Murai, Hezhao Zhao, Makoto Miyagishi, Vivi Kasim · 2017 · Science Advances
4. Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non–Cell Autonomous Liver Carcinogenesis
   Yuki Makino, Hayato Hikita, Kenji Fukumoto, Ji Hyun Sung, Yoshihiro Sakano, Kazuhiro Murai, Sadatsugu Sakane, Takahiro Kodama, Ryotaro Sakamori, Jumpei Kondo et al. · 2022 · Cancer Research
5. Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
   Jinze Shen, Qurui Wang, Yunan Mao, Wei Gao, Shiwei Duan · 2023 · MedComm
6. Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
   Mengyao Wu, Yilan Zhao, Chi Zhang, Kanyi Pu · 2024 · ACS Nano
7. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
   Qiong Yu, Yan Li, Kun Mu, Zhishuang Li, Qingyong Meng, Xiaojuan Wu, Yan Wang, Li Li · 2014 · Diagnostic Pathology
8. Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis
   Xiufang Xiong, Yongchao Zhao, Fei Tang, Dongping Wei, Daffyd G. Thomas, Xiang Wang, Yang Liu, Pan Zheng, Yi Sun · 2014 · eLife
9. Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System
   Beata Hat, Marek Kochańczyk, Marta N. Bogdał, Tomasz Lipniacki B · 2016 · PLoS Computational Biology
10. Mirror image proteins
    Le Zhao, Wuyuan Lu · 2014 · Current Opinion in Chemical Biology
11. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
    Maryam Zanjirband, Richard John Edmondson, John Lunec · 2016 · Oncotarget
12. Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit
    Bo Cao, Ziling Fang, Peng Liao, Xiang Yu Zhou, Jianping Xiong, Shelya X. Zeng, Hua Lu · 2017 · Oncotarget
13. Development of covalent inhibitors: Principle, design, and application in cancer
    Zheng, Lang, Li, Yang, Wu, Defa, Xiao, Huan, Zheng, Shilong, Wang, Guan, Sun, Qiu · 2023 · MedComm – Oncology
14. The Nucleolus and PARP1 in Cancer Biology
    Marina Engbrecht, Aswin Mangerich · 2020 · Cancers
15. Specificity and disease in the ubiquitin system
    Viduth K. Chaugule, Helen Walden · 2016 · Biochemical Society Transactions
16. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53
    Xi Su, Chao Feng, Simeng Wang, Liang Shi, Qingqing Gu, Haihong Zhang, Xinhui Lan, Yuelei Zhao, Wei Qiang, Meiju Ji et al. · 2021 · Cell Death and Differentiation
17. A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
    Mengxiong Wang, Laura Donatella Attardi · 2021 · Annual Review of Pathology Mechanisms of Disease
18. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
    Andrea Weilbacher, Matthias Gutekunst, Moshe Oren, Walter E. Aulitzky, Heiko van der Kuip · 2014 · Cell Death and Disease
19. Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression
    Rita Nahta, Fahd Al‐Mulla, Rabeah Abbas Al-Temaimi, Amedeo Amedei, Rafaela Andrade-Vieira, Sarah Bay, Dustin G. Brown, Gloria M. Calaf, Robert Craig Castellino, Karine Cohen-Solal et al. · 2015 · Carcinogenesis
20. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53
    Andreas C. Joerger, Matthias R. Bauer, Rainer Wilcken, Matthias G. J. Baud, Hannes Harbrecht, Thomas E. Exner, Frank M. Boeckler, John Spencer, Alan Roy Fersht · 2015 · Structure
21. Cellular senescence and protein degradation
    Xavier Deschênes‐Simard, Frédéric Lessard, Marie‐France Gaumont‐Leclerc, Nabeel M. Bardeesy, Gerardo Ferbeyre · 2014 · Cell Cycle
22. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo
    Hai Huang, Song Park, Haibo Zhang, Sijun Park, Wookbong Kwon, Enugyung Kim, Xiujuan Zhang, Soyoung Jang, Duhak Yoon, Seong‐Kyoon Choi et al. · 2021 · Journal of Experimental & Clinical Cancer Research
23. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
    Raymond S. Traweek, Brandon M. Cope, Christina Lynn Roland, Emily Zhi-Yun Keung, Elise F. Nassif, Derek J. Erstad · 2022 · Frontiers in Oncology
24. Senolytics: A Translational Bridge Between Cellular Senescence and Organismal Aging
    Harikrishnan Thoppil, Karl T. Riabowol · 2020 · Frontiers in Cell and Developmental Biology
25. Molecular landscape of prostate cancer: Implications for current clinical trials
    Galina Khemlina, Sadakatsu Ikeda, Razelle Kurzrock · 2015 · Cancer Treatment Reviews
26. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability
    Wei Zhao, Dan Lü, Liang Liu, Juan Cai, Yu Zhou, Ying Yang, Yu Zhang, Jun Zhang · 2017 · Oncotarget
27. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
    Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, Dhruv Chachad, Ran Zhao, Lauren E. Heese, Wencai Ma, Man Chun John Ma et al. · 2018 · Cancer Research
28. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode
    François Gessier, Joerg A. Kallen, Edgar Jacoby, Patrick Chêne, Therese‐Marie Stachyra, Stephan Ruetz, Sébastien Jeay, Philipp Holzer, Keiichi Masuya, Pascal Furet · 2015 · Bioorganic & Medicinal Chemistry Letters
29. MDMX contains an autoinhibitory sequence element
    Michał Biśta, Miriana Petrovich, Alan Roy Fersht · 2013 · Proceedings of the National Academy of Sciences
30. AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10‐mediated regulatory pathway
    Roman Hrstka, Pavla Bouchalová, Eva Michalová, Eva Matoulková, Petr Müller, Philip John Coates, Bořivoj Vojtěšek · 2015 · Molecular Oncology
31. Involvement of leptin in the molecular physiology of the placenta
    Malena Schanton, Julieta Lorena Maymó, Antonio Pérez‐Pérez, Víctor Sánchez‐Margalet, Cecilia Laura Varone · 2017 · Reproduction
32. A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer
    Xinkui Liu, Jiarui Wu, Dan Zhang, Kaihuan Wang, Xiaojiao Duan, Xiaomeng Zhang · 2018 · Evidence-based Complementary and Alternative Medicine
33. MicroRNA-410 Suppresses Migration and Invasion by Targeting MDM2 in Gastric Cancer
    Jianjun Shen, Weina Niu, Ming Zhou, Hongbo Zhang, Jun Ma, Ling Wang, Hongyan Zhang · 2014 · PLoS ONE · Retracted
34. Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention
    Chee Wai Fhu, Azhar Ali · 2021 · Cancers
35. The role of the ubiquitin-proteasome pathway in cancer development and treatment
    Fang-Bao Ding · 2014 · Frontiers in bioscience
36. Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction
    Michał Biśta, Siglinde Wolf, Kareem Khoury, Kaja Kowalska, Yijun Huang, Ewa Wrona, Marcelino Arciniega, Grzegorz M. Popowicz, Tad A. Holak, Alexander S. S. Dömling · 2013 · Structure
37. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma
    Liping Dai, Pengfei Ren, Mei Liu, Haruhiko Imai, Eng M. Tan, Jian Ying Zhang · 2014 · Clinical Immunology
38. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p
    Christina G. Towers, Anna L. Guarnieri, Douglas Scott Micalizzi, Joshua Chuck Harrell, Austin E. Gillen, Jihye Kim, Chu-An Wang, Michael U.J. Oliphant, David J. Drasin, Michelle A. Guney et al. · 2015 · Nature Communications
39. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
    Ravandi, Farhad, Gojo, Ivana, Patnaik, Mrinal M., Minden, Mark D., Kantarjian, Hagop, Johnson-Levonas, Amy O., Fancourt, Craig, Lam, Raymond, Jones, Mary Beth, Knox, Clayton D. et al. · 2016 · Leukemia Research
40. Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation
    Jiang‐Jiang Qin, Wei Wang, Sukesh Voruganti, Hui Wang, Weidong Zhang, Ruiwen Zhang · 2014 · Oncotarget
41. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling
    Cen Zhang, Juan Liu, Xiaolong Wang, Rui Wu, Meihua Lin, Saurabh V. Laddha, Qifeng Yang, Chang S. Chan, Zhaohui Feng · 2014 · Oncotarget
42. Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway
    Hao Ruan, Yu Chen, Xiaogang Niu, Weilin Zhang, Hanzhong Liu, Limin Chen, Ruoyao Xiong, Qi Sun, Changwen Jin, Ying Liu et al. · 2020 · Chemical Science
43. Targeting Ferroptosis by Ubiquitin System Enzymes: A Potential Therapeutic Strategy in Cancer
    Meng Yu, Huiyan Sun, Yayun Li, Shuang Zhao, Juan Su, Furong Zeng, Guangtong Deng, Xiang Chen · 2022 · International Journal of Biological Sciences
44. Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment
    Loredana Urso, Fiorella Calabrese, Adolfo Gino Favaretto, PierFranco Conte, Giulia Pasello · 2015 · Critical Reviews in Oncology/Hematology
45. Thymoquinone Anticancer Discovery: Possible Mechanisms
    Ali H. El‐Far · 2015 · Current Drug Discovery Technologies
46. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
    Phaik Ju Teoh, Wee Joo Chng · 2014 · BioMed Research International
47. The Deubiquitinating Enzyme USP24 Is a Regulator of the UV Damage Response
    Ling Zhang, Leah Nemzow, Hua Chen, Abigail Lubin, Xi Rong, Zhongyi Sun, Thomas K. Harris, Feng Gong · 2015 · Cell Reports
48. Two is better than one; toward a rational design of combinatorial therapy
    Sheng‐hong Chen, Galit Lahav · 2016 · Current Opinion in Structural Biology
49. Signal transduction pathways and resistance to targeted therapies in glioma
    Arata Tomiyama, Koichi Ichimura · 2019 · Seminars in Cancer Biology
50. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy
    Wei Wang, Jiang‐Jiang Qin, Sukesh Voruganti, Bhavitavya Nijampatnam, Sadanandan E. Velu, Ke‐He Ruan, Ming Hu, Jianwei Zhou, Ruiwen Zhang · 2018 · Cancer Research
51. Smart fermentation engineering for butanol production: designed biomass and consolidated bioprocessing systems
    Tao Zhao, Yukihiro Tashiro, Kenji Sonomoto · 2019 · Applied Microbiology and Biotechnology
52. De Novo Nano‐Erythrocyte Structurally Braced by Biomimetic Au(I)‐peptide Skeleton for MDM2/MDMX Predation toward Augmented Pulmonary Adenocarcinoma Immunotherapy
    Xiaoqiang Zheng, Jin Yan, Weiming You, Fanni Li, Jiajie Diao, Wangxiao He, Yu Yao · 2021 · Small
53. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity
    Yuqin Di, Xiaoqian Jing, Kunhua Hu, Xiangqiong Wen, Lvlan Ye, Xiang Zhang, Jiale Qin, Jinning Ye, Run Lin, Ziyang Wang et al. · 2022 · Drug Resistance Updates
54. Leptin Is an Anti-Apoptotic Effector in Placental Cells Involving p53 Downregulation
    Ayelén Rayen Toro, Julieta Lorena Maymó, Federico M. Ibarbalz, Antonio Pérez‐Pérez, Bernardo C Maskin, Alicia Graciela Faletti, Víctor Sánchez‐Margalet, Cecilia Laura Varone · 2014 · PLoS ONE
55. Molecular signature of anastasis for reversal of apoptosis
    Ho Man Tang, C. Conover Talbot, Ming Chiu Fung, Ho Lam Tang · 2017 · F1000Research
56. Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53
    Ruoji Zhou, An Xu, Julian A. Gingold, Louise C. Strong, Ruiying Zhao, Dung‐Fang Lee · 2017 · Trends in Pharmacological Sciences
57. CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer
    Jie Xie, Yan Li, Ke Jiang, Kaishun Hu, Sheng Zhang, Xiaorong Dong, Xiaofang Dai, Li Liu, Tao Zhang, Kunyu Yang et al. · 2017 · Theranostics
58. Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
    Edmund C.P. Chedgy, Gillian Rae Vandekerkhove, Cameron Herberts, Matti Annala, Adam Donoghue, Michael Sigouros, Elie J. Ritch, Werner Jan Struss, Saki Konomura, Janet Liew et al. · 2018 · The Journal of Pathology
59. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
    Yasutaka Hayashi, Susumu Goyama, Xiaoxiao Liu, Moe Tamura, Shuhei Asada, Yosuke Tanaka, Tomofusa Fukuyama, Mark Wunderlich, Eric Justin O'Brien, Benjamin E. Mizukawa et al. · 2019 · Nature Communications
60. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Alberto Puccini, Francesca Battaglin, Maria Laura Iaia, Heinz‐Josef Lenz, Mohamed E. Salem · 2020 · Journal for ImmunoTherapy of Cancer
61. Structure-based inhibition of protein–protein interactions
    Andrew M. Watkins, Paramjit S. Arora · 2014 · European Journal of Medicinal Chemistry
62. Inositol Polyphosphate Multikinase Is a Coactivator of P53-Mediated Transcription and Cell Death
    Xu, Risheng, Sen, Nilkantha, Paul, Bindu D., Snowman, Adele M., Rao, Feng, Vandiver, M. Scott, Xu, Jing, Snyder, Solomon H. · 2013 · Science Signaling
63. Pharmacological activation of wild-type p53 in the therapy of leukemia
    Kensuke Kojima, Jo Ishizawa, Michael Andreeff · 2016 · Experimental Hematology
64. Knockdown of Long Noncoding RNA PCAT6 Inhibits Proliferation and Invasion in Lung Cancer Cells
    Li Wan, Lin Zhang, Kai Fan, Zaixing Cheng, Quanchao Sun, Jianjun Wang · 2016 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
65. Secondary interaction between MDMX and p53 core domain inhibits p53 DNA binding.
    Wei, Xi, Wu, Shaofang, Song, Tanjing, Chen, Lihong, Gao, Ming, Borcherds, Wade, Daughdrill, Gary W., Chen, Jiandong · 2016 · Proceedings of the National Academy of Sciences
66. Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death
    Waqar Arif, Bhoomika Mathur, Michael Fadi Saikali, Ullas Valiya Chembazhi, Katelyn Toohill, You Jin Song, Qinyu Hao, Saman S. Karimi, Steven M. Blue, Brian A. Yee et al. · 2023 · Nature Communications
67. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
    Libero Santarpia, Giulia Bottai, Catherine Margaret Kelly, Balázs Győrffy, Borbála Székely, Lajos Pusztai · 2016 · The Oncologist
68. The Regulations of Deubiquitinase USP15 and Its Pathophysiological Mechanisms in Diseases
    Chon‐Kit Chou, Yu‐Ting Chang, Michal Kořínek, Yei‐Tsung Chen, Ya-Ting Yang, Steve Leu, I‐Ling Lin, Chin-Ju Tang, Chien‐Chih Chiu · 2017 · International Journal of Molecular Sciences
69. Proanthocyanidins with a Low Degree of Polymerization are Good Inhibitors of Digestive Enzymes Because of their Ability to form Specific Interactions: A Hypothesis
    Alma Angelica Vazquez-Flores, Alejandra Isabel Martinez-Gonzalez, Emilio ́Álvarez-Parrilla, Ángel G. Díaz‐Sánchez, Laura Alejandra De la Rosa, Gustavo Adolfo González-Aguilar, Cristóbal N. Aguilar · 2018 · Journal of Food Science
70. Proteomic characterization of post-translational modifications in drug discovery
    Linhui Zhai, Kai‐Feng Chen, Bingbing Hao, Minjia Tan · 2022 · Acta Pharmacologica Sinica
71. Organocatalytic, Diastereo- and Enantioselective Synthesis of Nonsymmetric cis -Stilbene Diamines: A Platform for the Preparation of Single-Enantiomer cis -Imidazolines for Protein–Protein Inhibition
    Brandon Vara, Anand Mayasundari, John C. Tellis, Michael W. Danneman, Vanessa Arredondo, Tyler A. Davis, Jaeki Min, Kristin E. Finch, Rodney Kiplin Guy, Jeffrey N. Johnston · 2014 · The Journal of Organic Chemistry
72. MiR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR
    Dan Jiang, William Chi Shing Cho, Zhenhao Li, Xiangrong Xu, Yuliang Qu, Zhongjia Jiang, Le Guo, Guangxian Xu · 2017 · Biomedicine & Pharmacotherapy
73. Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
    De-Hua Yu, Zhiyuan Xu, Shaowei Mo, Yuan Li, Xiangdong Cheng, Jiang‐Jiang Qin · 2020 · Frontiers in Oncology
74. Next Generation Therapeutics for the Treatment of Myelofibrosis
    Douglas A. Tremblay, John O Mascarenhas · 2021 · Cells
75. Autoinhibition of MDMX by intramolecular p53 mimicry
    Lihong Chen, Wade M. Borcherds, Shaofang Wu, Andreas Becker, E. Schönbrunn, Gary W. Daughdrill, Jiandong Chen · 2015 · Proceedings of the National Academy of Sciences
76. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation
    Jianzhong Chen, Jinan Wang, Qinggang Zhang, Kaixian Chen, Weiliang Zhu · 2015 · Scientific Reports
77. miR-641 Functions as a Tumor Suppressor by Targeting MDM2 in Human Lung Cancer
    Qinglong Kong, Nan Shu, Li Jun, Ning Xu · 2017 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · Retracted
78. An Update on MDMX and Dual MDM2/X Inhibitors
    Margarida Espadinha, Valentina Barcherini, Elizabeth A. Lopes, Maria M. M. Santos · 2018 · Current Topics in Medicinal Chemistry
79. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
    Ping Zhang, Isaac Kitchen-Smith, Lingyun Xiong, Giovanni Stracquadanio, Katherine A. Brown, Philipp Richter, Marsha D. Wallace, Elisabeth E. Bond, Natasha Sahgal, Samantha Moore et al. · 2021 · Cancer Research
80. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53
    Alyssa M. Klein, Lynn Biderman, David Tong, Bita Alaghebandan, Sakina A. Plumber, Helen S. Mueller, Anne E. van Vlimmeren, Chen Katz, Carol L. Prives · 2021 · Proceedings of the National Academy of Sciences
81. Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes
    S. P. Singh, Rakesh Bhaskar, Shampa Ghosh, Bhuvaneshwar Yarlagadda, Dr. Krishna Kumar Singh, Prashant Verma, Sonali Sengupta, Mitko I. Mladenov, Nikola Hadzi‐Petrushev, Radoslav Stojchevski et al. · 2025 · Cancers
82. Targeting ubiquitination in disease and therapy
    Xiaojuan Yang, Tian Lan, Buzhe Zhang, Xue Tao, Weili Qi, Kunlin Xie, Yunshi Cai, Chang Liu, Junhong Han, Hong Mei Wu · 2025 · Signal Transduction and Targeted Therapy
83. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis
    Cen Zhang, Juan Liu, Chunwen Tan, Xuetian Yue, Yuhan Zhao, Jiaping Peng, Xiaolong Wang, Saurabh V. Laddha, Chang S. Chan, Shu Sen Zheng et al. · 2016 · Oncotarget
84. Design of highly stabilized nanocomposite inks based on biodegradable polymer-matrix and gold nanoparticles for Inkjet Printing
    Belén Begines, Ana Alcudia, José Raúl Aguilera-Velázquez, Guillermo Martínez, Yinfeng He, Gustavo F. Trindade, Ricky D. Wildman, María Jesús Sayagués, Aila Jimenez‐Ruiz, Rafael Prado‐Gotor · 2019 · Scientific Reports
85. The Effect of Dysfunctional Ubiquitin Enzymes in the Pathogenesis of Most Common Diseases
    Gizem Çelebi Torabfam, Hale Kesim, Ebru Ozer, Özlem Kutlu · 2020 · International Journal of Molecular Sciences
86. Adaptation and learning of molecular networks as a description of cancer development at the systems-level: Potential use in anti-cancer therapies
    Dávid M. Gyurkó, Dániel V. Veres, Dezső Módos, Katalin Lenti, Tamás Korcsmáros, Péter Csermely · 2013 · Seminars in Cancer Biology
87. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
    Tom Van Maerken, Ali Rihani, Alan Van Goethem, Anne De Paepe, Frank Speleman, Jo Vandesompele · 2013 · Cancer Letters
88. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions
    Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu, Yujun Zhao · 2021 · Journal of Medicinal Chemistry
89. Insights into regulators of p53 acetylation
    Nagasaka, Mai, Miyajima, Chiharu, Aoki, Hiromasa, Aoyama, Mineyoshi, Morishita, Daisuke, Inoue, Yasumichi, Hayashi, Hidetoshi · 2022 · Cells
90. Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art
    Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Marcela Tavares Luiz, Jennifer Thayanne Cavalcante de Araújo, Marlus Chorilli · 2020 · Current Neuropharmacology
91. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties
    Joana Soares, Margarida Espadinha, Liliana Raimundo, Helena Ramos, Ana Sara Gomes, Sara Gomes, Joana B. Loureiro, Alberto Inga, Flávio Reis, Célia M. F. Gomes et al. · 2017 · Molecular Oncology
92. MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells
    Benfan Wang, Hong Wu, Chengsen Chai, John D. Lewis, Flavia Pichiorri, David D. Eisenstat, Scott L. Pomeroy, Roger P. Leng · 2017 · Cancer Letters
93. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
    Jessica J. Miller, Christian Gaiddon, Tim Storr · 2020 · Chemical Society Reviews
94. Directed Disulfide Pairing and Folding of Peptides for the De Novo Development of Multicyclic Peptide Libraries
    Shuaimin Lu, Yapei Wu, Jinjing Li, Xiaoting Meng, Chenliang Hu, Yibing Zhao, Chuanliu Wu · 2020 · Journal of the American Chemical Society
95. Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
    Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson · 2020 · Molecules
96. Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on Lung Cancer for Overcoming Drug Resistance
    Xinyi Wang, Zhikun Liu, Yuanjiang Wang, Shaohua Gou · 2022 · Journal of Medicinal Chemistry
97. New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
    Juliane Margarete Jürgensmeier, Joseph P. Eder, Roy S. Herbst · 2014 · Clinical Cancer Research
98. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting
    Franziska Wachter, Ann M. Morgan, Marina Godes, Rida Mourtada, Gregory H. Bird, Loren D. Walensky · 2016 · Oncogene
99. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies
    Jian Wu, Suresh Kumar, Feng Wang, Hui Wang, Lijia Chen, Patrick Arsenault, Michael R. Mattern, Joseph Weinstock · 2017 · Journal of Medicinal Chemistry
100. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery
     Zhenyuan Bian, Jin Yan, Simeng Wang, Yijie Li, Yi Guo, Bohan Ma, Hao Guo, Zhijie Lei, Chun Yin, Yi Zhou et al. · 2018 · Theranostics